Penumbra logo
Penumbra PEN
$ 336.45 0.05%

Annual report 2025
added 02-25-2026

report update icon

Penumbra Financial Statements 2011-2026 | PEN

Annual Financial Statements Penumbra

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

13.2 B 10.4 B 10.1 B 9.9 B 8.15 B 10.2 B 6.19 B 4.88 B 3.34 B 2.16 B 513 M 13.6 M - - -

Shares

38.9 M 38.6 M 38.4 M 37.8 M 36.8 M 35.8 M 34.8 M 34.1 M 33 M 30.5 M 12 M 22.7 M - - -

Historical Prices

339 270 262 261 222 284 166 134 108 76.8 46.6 - - - -

Net Income

178 M 14 M 91 M -2 M 5.28 M -15.7 M 48.5 M 6.6 M 4.66 M 14.8 M 2.36 M 2.24 M 4.1 M 1.96 M -

Revenue

1.4 B 1.19 B 1.06 B 847 M 748 M 560 M 547 M 445 M 334 M 263 M 186 M 126 M 88.8 M 73.1 M -

Cost of Revenue

461 M 440 M 376 M 312 M 272 M 222 M 175 M 152 M 117 M 92.5 M 62 M 42.7 M 31 M - -

Gross Profit

942 M 755 M 683 M 535 M 475 M 338 M 372 M 293 M 217 M 171 M 124 M 82.8 M 57.9 M 49 M -

Operating Income

189 M 9.28 M 73.6 M 6.08 M -7.5 M -38.9 M 47.5 M -852 K 1.16 M -1.35 M 4.18 M 3.01 M -1.13 M - -

Interest Expense

893 K -682 K 1.01 M -2.33 M 1.93 M -343 K -227 K -504 K -1.34 M -1.84 M -696 K -309 K -474 K - -

EBITDA

207 M 33 M 101 M 30.4 M 8.91 M -26.1 M 55.6 M 36.2 M 4.95 M 947 K 5.93 M 3.76 M -449 K 3.43 M -

Operating Expenses

753 M 746 M 609 M 529 M 483 M 377 M 324 M 263 M 216 M 172 M 120 M 79.8 M 59 M 45.5 M -

General and Administrative Expenses

663 M 574 M 506 M 450 M 378 M 287 M 273 M 226 M 184 M 148 M 102 M - - - -

All numbers in USD currency

Quarterly Income Statement Penumbra

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

39.1 M 38.8 M 38.6 M 38.6 M 38.8 M 38.7 M 38.5 M 38.3 M 38.2 M - 37.9 M 37.8 M 37.6 M 37.5 M 36.6 M 36.5 M 36.5 M 36.4 M 36.2 M 35.4 M 35 M 35 M 34.8 M 34.7 M 34.5 M 34.4 M 34.2 M 34.1 M 33.8 M 33.6 M 33.4 M 33.2 M 31.6 M 31 M 30.6 M 30.2 M 30 M 29.9 M 7.85 M 5.1 M 4.9 M 4.7 M 4.69 M 4.61 M 4.43 M - - - - - - - - - - - -

Net Income

45.9 M 45.3 M 39.2 M 29.5 M -60.2 M 11 M 9.21 M 19 M 8.56 M - -2.27 M -3.69 M 79 K -24.6 M 8.85 M 8.3 M 10.9 M 3.65 M -8.82 M -12 M 1.42 M 9.69 M 11.5 M 16.6 M 10.7 M 6.66 M -18.9 M 13.4 M 5.49 M 9.08 M 238 K -1.56 M -3.11 M -2.4 M 11.9 M 3.01 M 2.29 M 1.63 M 901 K -2.67 M 2.5 M 416 K 172 K 391 K 1.27 M - - - - - - - - - - - -

Revenue

355 M 339 M 324 M 301 M 299 M 279 M 271 M 261 M 241 M - 214 M 208 M 204 M 204 M 190 M 184 M 169 M 167 M 151 M 105 M 137 M 145 M 140 M 134 M 128 M 121 M 112 M 110 M 103 M 96.1 M 83.9 M 80.6 M 73.2 M 73.1 M 67.2 M 65.1 M 57.9 M 54.4 M 50.4 M 42.3 M 39 M 35.4 M 32.5 M 31.5 M 26.2 M - - - - - - - - - - - -

Cost of Revenue

114 M 115 M 108 M 101 M 137 M 97.5 M 93.2 M 94.6 M 90.3 M - 78.4 M 74.3 M 76.5 M 78.6 M 70.2 M 65.6 M 57.9 M 72.6 M 60.2 M 40.2 M 49.3 M 47.1 M 43.5 M 40.3 M 44.5 M 42.1 M 36.8 M 37.4 M 36.1 M 32.3 M 29.1 M 29.7 M 25.5 M 26.5 M 24.3 M 23.6 M 18 M 18 M 16.9 M 14.9 M 12.2 M 11.5 M 11.7 M 10.8 M 8.71 M - - - - - - - - - - - -

Gross Profit

240 M 224 M 216 M 200 M 163 M 181 M 178 M 167 M 151 M - 135 M 134 M 127 M 125 M 120 M 119 M 111 M 94.3 M 90.9 M 64.9 M 88 M 98.1 M 96 M 93.9 M 83.9 M 78.7 M 75 M 72.3 M 66.6 M 63.7 M 54.8 M 50.9 M 47.7 M 46.6 M 42.9 M 41.5 M 39.9 M 36.5 M 33.5 M 27.4 M 26.7 M 23.9 M 20.8 M 20.7 M 17.5 M - - - - - - - - - - - -

Operating Income

48.8 M 40.8 M 40.4 M 35.4 M -81 M 12.1 M 12.6 M 17.9 M 8.01 M - 5.43 M -139 K -4.05 M - 8.78 M 10.3 M 13.5 M - -20.2 M -17.6 M 610 K - 13 M 12.8 M 11.2 M - -20.8 M 9.28 M 4.04 M - 683 K -1.33 M -2.05 M - -1.36 M -670 K 1.84 M - 2.18 M -3.81 M 3.99 M - 311 K - - - - - - - - - - - - - -

Interest Expense

-535 K 812 K 445 K 1.28 M -226 K -366 K -444 K 444 K 416 K - -2.36 M -956 K -1.01 M - -1.14 M -408 K -1.48 M - 14 K 511 K -1.66 M - -772 K -71 K 24 K - 170 K -340 K -290 K - -102 K -214 K -349 K - -360 K -272 K -224 K - -115 K -542 K 44 K - -56 K - - - - - - - - - - - - - -

EBITDA

49 M 41 M 45.4 M 35.5 M -78.4 M 19.6 M 15.2 M 20.4 M 14.6 M - 7.98 M 1.9 M 1.68 M - 19.4 M 10.6 M 16.9 M - -10.7 M -11.6 M 3.57 M - 18.8 M 16.5 M 13 M - -16.4 M 12.2 M 5.44 M - 3.26 M 94 K -1.39 M - -663 K -70 K 2.37 M - 2.68 M -3.41 M 4.33 M - 511 K - - - - - - - - - - - - - -

Operating Expenses

192 M 183 M 176 M 165 M 244 M 169 M 165 M 149 M 143 M - 130 M 134 M 131 M 166 M 111 M 108 M 97.9 M 96.1 M 111 M 82.6 M 87.4 M 87.5 M 83 M 81.1 M 72.8 M 72 M 95.9 M 63 M 62.5 M 59.9 M 54.1 M 52.3 M 49.8 M - 44.2 M 42.1 M 38.1 M - 31.3 M 31.2 M 22.7 M - 20.5 M - - - - - - - - - - - - - -

General and Administrative Expenses

169 M 160 M 153 M 140 M 142 M 144 M 126 M 127 M 123 M - 109 M 115 M 111 M - 94.4 M 90.6 M 79.8 M - 76.2 M 59.9 M 74.5 M - 69.3 M 67.7 M 61.1 M - 55.9 M 54.8 M 54.5 M - 46 M 44.2 M 42.7 M - 37.7 M 35.9 M 33.1 M - 26.8 M 26.4 M 19.5 M - 16.6 M - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Penumbra PEN
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Penumbra plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Medtronic PLC Medtronic PLC
MDT
$ 88.33 0.51 % $ 114 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 9.2 - $ 330 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 219.23 1.49 % $ 15.4 B usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 36.79 -0.65 % $ 1.14 B usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Electromed Electromed
ELMD
$ 24.85 0.77 % $ 210 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Sintx Technologies Sintx Technologies
SINT
$ 2.56 - $ 7.1 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.62 -7.64 % $ 33.7 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 2.37 2.16 % $ 3.7 M usaUSA
Stryker Corporation Stryker Corporation
SYK
$ 330.3 0.84 % $ 126 B usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 32.44 -0.03 % $ 23.8 B britainBritain
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
$ 4.1 -2.84 % $ 66.9 M usaUSA
TELA Bio TELA Bio
TELA
$ 0.74 6.98 % $ 34.7 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 64.35 1.66 % $ 3.51 B britainBritain
InspireMD InspireMD
NSPR
$ 1.74 -0.57 % $ 112 M israelIsrael
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 11.43 0.35 % $ 1.54 B usaUSA
MiMedx Group MiMedx Group
MDXG
$ 4.07 -0.85 % $ 602 M usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 23.53 -3.03 % $ 1.6 B usaUSA
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
$ 2.34 1.97 % $ 137 M israelIsrael
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 16.52 1.76 % $ 388 M usaUSA
Myomo Myomo
MYO
$ 0.71 2.05 % $ 29.7 M usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
$ 50.87 -1.05 % $ 1.49 B usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.29 -1.15 % $ 52.5 M usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 9.37 0.16 % $ 364 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA